

Claims:

1. The use of an agent prepared from plant seedlings enriched with electrolytes for the production of a pharmaceutical preparation aimed to proliferate T-lymphocytes in non-immune-suppressed persons.
2. The use according to claim 1, characterized in that CD3+-specific immune cells are proliferated.
3. The use according to claim 1 or 2, characterized in that CD3+/CD4+-specific immune cells (helper cells) are proliferated.
4. The use according to any one of claims 1 to 3, characterized in that CD3-/CD16,56+-specific immune cells (natural killer cells) are proliferated.
5. The use according to any one of claims 1 to 4, characterized in that CD4+/CD45RA+-specific immune cells (naive T-cells) are proliferated.
6. The use according to any one of claims 1 to 5, characterized in that CD3+/CD8+-specific immune cells (suppressor cells) are proliferated.
7. The use of an agent prepared from plant seedlings enriched with electrolytes for the production of a pharmaceutical preparation aimed to reduce cholesterol concentration in blood.
8. The use of an agent prepared from plant seedlings enriched with electrolytes for the production of a pharmaceutical preparation aimed to reduce low-density lipoprotein (LDL) concentration in blood.
9. The use according to any one of claims 1 to 8, characterized in that said pharmaceutical preparation is used in the geriatric field.
10. The use according to any one of claims 1 to 9, characterized in that said pharmaceutical preparation is provided in food

form.

11. The use according to any one of claims 1 to 10, characterized in that said pharmaceutical preparation is used to prevent atherosclerosis.

12. The use according to any one of claims 1 to 10, characterized in that said pharmaceutical preparation is used to prevent myocardial infarct.

13. The use according to any one of claims 1 to 10, characterized in that said pharmaceutical preparation is used to prevent apoplexy.